Skip to main content
. 2015 Feb 3;45(5):439–448. doi: 10.1093/jjco/hyv011

Figure 2.

Figure 2.

Kaplan–Meier estimates for overall survival by maximum diastolic blood pressure during Cycle 1 for axitinib/gemcitabine vs. placebo/gemcitabine in the overall study population (A), and in patients in Japan (B), North America (C) and the European Union (D).